钠-葡萄糖共转运蛋白 2 抑制剂在慢性肾脏病治疗中的作用：小型综述。
A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
机构信息
Department of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China,
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China,
出版信息
Kidney Blood Press Res. 2023;48(1):599-610. doi: 10.1159/000534174. Epub 2023 Sep 16.
BACKGROUND
Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement and direct effects, independent of glucose-lowering effects.
SUMMARY
In patients with diabetic kidney disease (DKD), several studies have demonstrated the potential nephroprotective mechanisms of SGLT2 inhibitors, and evidence of nephroprotective mechanisms in the non-DKD population is accumulating. Although the nephroprotective mechanism of SGLT2 inhibitors has not been fully elucidated, several laboratory studies have illustrated the mechanism underlying the effects of SGLT2 inhibitors at various aspects.
KEY MESSAGES
The purpose of this article is to review the mechanism of nephroprotective effect of SGLT2 inhibitors and to look forward to promising research in the future.
背景
钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂是一种新型的降糖药物，已在多项临床研究中证实具有降糖和肾脏保护作用，其肾脏保护作用既包括代谢改善的间接作用，也包括独立于降糖作用的直接作用。
总结
在糖尿病肾病（DKD）患者中，多项研究已经证实了 SGLT2 抑制剂的潜在肾脏保护机制，并且在非 DKD 人群中积累了越来越多的肾脏保护机制证据。虽然 SGLT2 抑制剂的肾脏保护机制尚未完全阐明，但一些实验室研究已经从各个方面说明了 SGLT2 抑制剂作用的机制。
关键信息
本文旨在综述 SGLT2 抑制剂肾脏保护作用的机制，并对未来有前景的研究进行展望。
Zotero 插件